Abstract
A better understanding of predisposition to transition to high-dose, long-term opioid therapy after initial opioid receipt could facilitate efforts to prevent opioid use disorder (OUD). We extracted data on 69,268 patients in the Veterans Aging Cohort Study who received any opioid prescription between 1998 and 2015. Using latent growth mixture modelling, we identified four distinguishable dose trajectories: low (53%), moderate (29%), escalating (13%), and rapidly escalating (5%). Compared to low dose trajectory, those in the rapidly escalating dose trajectory were proportionately more European-American (59% rapidly escalating vs. 38% low); had a higher prevalence of HIV (31% vs. 29%) and hepatitis C (18% vs. 12%); and during follow-up, had a higher incidence of OUD diagnoses (13% vs. 3%); were hospitalised more often [18.1/100 person-years (PYs) vs. 12.5/100 PY]; and had higher all-cause mortality (4.7/100 PY vs. 1.8/100 PY, all p < 0.0001). These measures can potentially be used in future prevention research, including genetic discovery.
Similar content being viewed by others
References
Dobscha SK, Corson K, Flores JA, Tansill EC, Gerrity MS. Veterans Affairs Primary Care Clinicians’ attitudes toward chronic pain and correlates of opioid prescribing rates. Pain Med. 2008;9(5):564–71.
Gironda RJ, Clark ME, Massengale JP, Walker RL. Pain among Veterans of Operations Enduring Freedom and Iraqi Freedom. Pain Med. 2006;7(4):339–43.
Fayaz A, Croft P, Langford RM, Donaldson LJ, Jones GT. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open. 2016;6(6):e010364.
Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010. https://doi.org/10.1001/archinternmed.2010.391.
Bohnert ASB, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. J Am Med Assoc. 2011;305(13):1315–21.
Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, et al. Opioid prescriptions for chronic pain and overdose. Ann Intern Med. 2010;152:85–92.
Dowell D, Haegerich T, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. J Am Med Assoc. 2016. https://doi.org/10.1001/jama.2016.1464.(epub).
The Opioid Therapy for Chronic Pain Work Group. In: Department of Veterans Affairs, Department of Defense, editors. VA/DoD clinical practice guideline for opioid therapy for chronic pain. 2017.
Dowell D, Haegerich T, Chou R. CDC guideline for prescribing opioids for chronic pain—United States 2016. MMWR Recomm Rep. 2016;65(No. RR-1):1–49.
Faculty of Pain Medicine. Opioids aware: a resource for patients and healthcare professionals to support prescribing of opioid medicines for pain. http://www.fpm.ac.uk/faculty-of-pain-medicine/opioids-aware. Accessed 8 Jun 2019.
Hauser W, Bock F, Engeser P, Hege-Scheuing G, Huppe M, Lindena G, et al. Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain. Schmerz. 2015;29(1):109–30.
Morasco BJ, Duckart JP, Carr TP, Deyo RA, Dobscha SK. Clinical characteristics of Veterans prescribed high doses of opioid medications for chronic non-cancer pain. PAIN®. 2010;151(3):625–32.
Sullivan MD, Edlund MJ, Fan M-Y, DeVries A, Braden JB, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP Study. Pain. 2008;138(2):440–9.
Edlund MJ, Martin BC, Fan M-Y, Braden JB, Devries A, Sullivan MD. An analysis of heavy utilizers of opioids for chronic noncancer pain in the TROUP Study. J Pain Symptom Manag. 2010;40(2):279–89.
Gelernter J, Kranzler HR, Sherva R, Koesterer R, Almasy L, Zhao H, et al. Genome-wide association study of opioid dependence: multiple associations mapped to calcium and potassium pathways. Biol Psychiatry. 2014;76(1):66–74.
Cheng Z, Zhou H, Sherva R, Farrer LA, Kranzler HR, Gelernter J. Genome-wide association study identifies a regulatory variant of RGMA associated with opioid dependence in European Americans. Biol Psychiatry. 2018. https://doi.org/10.1016/j.biopsych.2017.12.016.
Nelson EC, Agrawal A, Heath AC, Bogdan R, Sherva R, Zhang B, et al. Evidence of CNIH3 involvement in opioid dependence. Mol Psychiatry. 2015. https://doi.org/10.1038/mp.2015.102.
Li D, Zhao H, Kranzler HR, Li MD, Jensen KP, Zayats T, et al. Genome-wide association study of copy number variations (CNVs) with opioid dependence. Neuropsychopharmacology. 2015;40(4):1016–26.
Smith AH, Jensen KP, Li J, Nunez Y, Farrer LA, Hakonarson H, et al. Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. Mol Psychiatry. 2017;22(3):346–52.
Edelman EJ, Gordon K, Becker WC, Goulet JL, Skanderson M, Gaither JR, et al. Receipt of opioid analgesics by HIV-infected and uninfected patients. J Gen Intern Med. 2013;28(1):82–90.
Becker WC, Gordon K, Edelman EJ, Kerns RD, Crystal S, Dziura JD, et al. Trends in any and high-dose opioid analgesic receipt among aging patients with and without HIV. AIDS Behav. 2016;20(3):679–86.
Weisberg DF, Gordon KS, Barry DT, Becker WC, Crystal S, Edelman EJ, et al. Long-term prescription of opioids and/or benzodiazepines and mortality among HIV-infected and uninfected patients. J Acquir Immune Defic Syndr. 2015;69(2):223–33.
Edelman EJ, Gordon KS, Crothers K, Akgun K, Bryant KJ, Becker WC, et al. Association of prescribed opioids with increased risk of community-acquired pneumonia among patients with and without HIV. JAMA Intern Med. 2019. https://doi.org/10.1001/jamainternmed.2018.6101.
Wiese AD, Griffin MR, Schaffner W, Stein CM, Greevy RA, Mitchel EF Jr, et al. Opioid analgesic use and risk for invasive pneumococcal diseases: a nested case–control study. Ann Intern Med. 2018;168(6):396–404.
Fultz SL, Skanderson M, Mole L, Gandhi N, Bryant K, Crystal S, et al. Development and verification of a “virtual” cohort using the national VA Health Information System. Med Care. 2006;44(8):S25–30.
Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Veterans Aging Cohort Study (VACS): overview and description. Med Care. 2006;44(8):S13–24.
Justice AC, Modur S, Tate J, Althoff K, Jacobson LP, Gebo KA, et al. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr. 2013;62(2):149–63.
Akgun KM, Gordon K, Pisani M, Fried T, McGinnis KA, Tate JP, et al. Risk factors for hospitalization and medical intensive care unit (MICU) admission among HIV-infected Veterans. J Acquir Immune Defic Syndr. 2013;62(1):52–9.
Akgun KM, Tate JP, Crothers K, Crystal S, Leaf DA, Womack J, et al. An adapted frailty-related phenotype and the VACS index as predictors of hospitalization and mortality in HIV-infected and uninfected individuals. J Acquir Immune Defic Syndr. 2014;67(4):397–404.
Escota GV, Patel P, Brooks JT, Bush T, Conley L, Baker J, et al. Short communication: the Veterans Aging Cohort Study Index is an effective tool to assess baseline frailty status in a contemporary cohort of HIV-infected persons. AIDS Res Hum Retroviruses. 2015;31(3):313–7.
Marquine MJ, Umlauf A, Rooney AS, Fazeli PL, Gouaux BD, Paul Woods S, et al. The Veterans Aging Cohort Study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr. 2014;65(2):190–7.
Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013;27(4):563–72.
Womack JA, Goulet JL, Gibert C, Brandt CA, Skanderson M, Gulanski B, et al. Physiologic frailty and fragility fracture in HIV-infected male Veterans. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;56(10):1498–504.
Altman M. In: Lewis-Beck M, Bryman AE, Liao TF, editors. Encyclopedia of social science research methods. Thousand Oaks: Sage Publications; 2004.
Jones BL, Nagin DS. Advances in group-based trajectory modeling and an SAS procedure for estimating them. Sociol Methods Res. 2007;35(4):542–71.
Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2001;29(3):374–93.
Nagin D. Group-based modeling of development. Cambridge: Harvard University Press; 2005.
Palmer RH, Brick L, Nugent NR, Bidwell LC, McGeary JE, Knopik VS, et al. Examining the role of common genetic variants on alcohol, tobacco, cannabis and illicit drug dependence: genetics of vulnerability to drug dependence. Addiction. 2015;110(3):530–7.
Goulet JL, Brandt C, Crystal S, Fiellin DA, Gibert C, Gordon AJ, et al. Agreement between electronic medical record-based and self-administered pain numeric rating scale: clinical and research implications. Med Care. 2013;51(3):245–50.
Breivik H, Borchgrevink PC, Allen SM, Rosseland LA, Romundstad L, Hals EK, et al. Assessment of pain. Br J Anaesth. 2008;101(1):17–24.
Banta-Green CJ, Merrill JO, Doyle SR, Boudreau DM, Calsyn DA. Opioid use behaviors, mental health and pain—development of a typology of chronic pain patients. Drug Alcohol Depend. 2009;104(1–2):34–42.
Gagnon B, Scott S, Nadeau L, Lawlor PG. Patterns of community-based opioid prescriptions in people dying of cancer. J Pain Symptom Manag. 2015;49(1):36–44.e1.
Guarino H, Marsch LA, Deren S, Straussner SL, Teper A. Opioid use trajectories, injection drug use, and hepatitis C virus risk among young adult immigrants from the Former Soviet Union living in New York City. J Addict Dis. 2015;34(2–3):162–77.
Hser YI, Huang D, Saxon AJ, Woody G, Moskowitz AL, Matthews AG, et al. Distinctive trajectories of opioid use over an extended follow-up of patients in a multisite trial on buprenorphine + naloxone and methadone. J Addict Med. 2017;11(1):63–9.
Monga N, Rehm J, Fischer B, Brissette S, Bruneau J, El-Guebaly N, et al. Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal opioid users. Drug Alcohol Depend. 2007;88(1):1–8.
Naumann RB, Marshall SW, Gottfredson NC, Lund JL, Ringwalt CL, Skinner AC. Trajectories of dispensed prescription opioids among beneficiaries enrolled in a Medicaid controlled substance “lock-in” program. Pharmacoepidemiol Drug Saf. 2018. https://doi.org/10.1002/pds.4445.
Barnett ML, Olenksi AR, Jena AB. Opioid prescribing by emergency physicians and risk of long-term use. N Engl J Med. 2017;376(19):1896.
Burgess DJ, Nelson DB, Gravely AA, Bair MJ, Kerns RD, Higgins DM, et al. Racial differences in prescription of opioid analgesics for chronic noncancer pain in a national sample of Veterans. J Pain. 2014;15(4):447–55.
Hoffman KM, Trawalter S, Axt JR, Oliver MN. Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites. Proc Natl Acad Sci USA. 2016;113(16):4296–301.
Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.
Schranz AJ, Barrett J, Hurt CB, Malvestutto C, Miller WC. Challenges facing a rural opioid epidemic: treatment and prevention of HIV and hepatitis C. Curr HIV/AIDS Rep. 2018;15(3):245–54.
Ogdie A, Pang WG, Forde KA, Samir BD, Mulugeta L, Chang KM, et al. Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection. BMC Musculoskelet Disord. 2015;16:93.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Publishers; 2013.
Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. N Engl J Med. 2019. https://doi.org/10.1056/NEJMp1904190.
Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE Randomized Clinical Trial. JAMA. 2018;319(9):872–82.
Acknowledgements
This work was supported by US National Institutes of Health, including Grants from National Institute on Alcohol Abuse and Alcoholism (U24-AA020794, U01-AA020790, U10-AA013566-completed to ACJ) and National Institute on Drug Abuse (NIDA R01-DA040471, R01-DA12690). Additional support was provided by the US Department of Veterans Affairs (i01-BX003341), Yale School of Medicine Drug Use, Addiction, and HIV Research Scholars Program (DAHRS K12-DA033312), and Agency for Healthcare Research and Quality (AHRQ U19-HS021112 and R18-HS023258). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The views presented in this paper are the authors’ and not necessarily those of the Department of Veterans Affairs or the United States Government.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
Dr. Kranzler is a Member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, and XenoPort. Drs. Kranzler, Gelernter, and A. Smith are also named as Inventors on PCT Patent Application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. The remaining authors have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Rentsch, C.T., Edelman, E.J., Justice, A.C. et al. Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study. AIDS Behav 23, 3340–3349 (2019). https://doi.org/10.1007/s10461-019-02608-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-019-02608-3